BRPI0516003A - composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos - Google Patents

composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos

Info

Publication number: BRPI0516003A
Authority: BR; Brazil
Prior art keywords: compound; hydrate; ester; pharmaceutically acceptable; acceptable salt
Prior art date: 2004-10-12

Application number

BRPI0516003-0A

Other languages

English (en)

Inventor

Nian Zhou

Jasbir Singh

Mark Gurney

Georgeta Hategan

Peng Yu

David Zembower

Original Assignee

Decode Genetics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-12

Filing date

2005-06-27

Publication date

2008-04-29

2005-06-27 Application filed by Decode Genetics Inc filed Critical Decode Genetics Inc

2008-04-29 Publication of BRPI0516003A publication Critical patent/BRPI0516003A/pt

Links

150000001875 compounds Chemical class 0.000 title abstract 4
150000002148 esters Chemical class 0.000 title 1
238000000338 in vitro Methods 0.000 title 1
239000003446 ligand Substances 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
102000017953 prostanoid receptors Human genes 0.000 title 1
108050007059 prostanoid receptors Proteins 0.000 title 1
150000003839 salts Chemical class 0.000 title 1
238000012216 screening Methods 0.000 title 1
-1 Acyl sulfonamide Chemical class 0.000 abstract 1
125000002619 bicyclic group Chemical group 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
238000011321 prophylaxis Methods 0.000 abstract 1
150000003180 prostaglandins Chemical class 0.000 abstract 1
229940124530 sulfonamide Drugs 0.000 abstract 1
238000011282 treatment Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
- C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
- C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Virology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Surgery (AREA)
Molecular Biology (AREA)

BRPI0516003-0A 2004-10-12 2005-06-27 composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos BRPI0516003A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US61817204P	2004-10-12	2004-10-12
PCT/US2005/023009 WO2006044000A1 (en)	2004-10-12	2005-06-27	Sulfonamide pert-substituted bicyclics for occlusive artery disease

Publications (1)

Publication Number	Publication Date
BRPI0516003A true BRPI0516003A (pt)	2008-04-29

Family

ID=35229642

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0516003-0A BRPI0516003A (pt)	2004-10-12	2005-06-27	composto, uso em um composto ou um éster, um sal farmaceuticamente aceitável ou um hidrato do mesmo, formulação farmacêutica, e, método para a triagem in vitro de ligandos de receptor de prostanóide seletivos

Country Status (16)

Country	Link
US (2)	US7598397B2 (pt)
EP (1)	EP1812388B1 (pt)
JP (1)	JP2008515971A (pt)
KR (1)	KR20070091607A (pt)
CN (1)	CN101142184A (pt)
AT (1)	ATE499344T1 (pt)
AU (1)	AU2005296305A1 (pt)
BR (1)	BRPI0516003A (pt)
CA (1)	CA2583667A1 (pt)
DE (1)	DE602005026553D1 (pt)
IL (1)	IL182488A0 (pt)
MX (1)	MX2007004525A (pt)
NO (1)	NO20072288L (pt)
NZ (1)	NZ554491A (pt)
RU (1)	RU2403240C2 (pt)
WO (1)	WO2006044000A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4964593B2 (ja) *	2003-09-25	2012-07-04	セノメドバイオサイエンシーズ，エルエルシー	神経学的病状の治療用のテトラヒドロインドロン誘導体
CN101076531A (zh) *	2004-10-12	2007-11-21	解码遗传学公司	用于阻塞性血管疾病的羧酸迫位取代的双环化合物
MX2007004525A (es) *	2004-10-12	2007-09-19	Decode Genetics Inc	Sulfonamidas biciclicas peri-sustituidas para enfermedad de arteria oclusiva.
JP4094660B1 (ja) *	2005-08-10	2008-06-04	武田薬品工業株式会社	糖尿病治療剤
WO2007137040A2 (en) *	2006-05-16	2007-11-29	Decode Genetics Ehf	7-(acryloyl) indole compositions and methods for making and using same
CA2652152A1 (en) *	2006-05-16	2007-11-29	Decode Genetics Ehf	Process for preparing 7-(acryloyl)indoles
CA2654811A1 (en) *	2006-06-12	2007-12-21	Merck Frosst Canada Ltd.	Indoline amide derivatives as ep4 receptor ligands
WO2008127275A2 (en) *	2006-09-22	2008-10-23	Ptc Therapeutics, Inc.	Pyrrolinone compounds as inhibitors of bacterial peptidyl trna hydrolase and uses thereof
TW200843739A (en)	2007-03-30	2008-11-16	Shionogi & Co	Novel pyrrolinone derivative and composition containing the same
WO2009062134A1 (en) *	2007-11-09	2009-05-14	Cenomed Biosciences, Llc	Treatment of post-traumatic stress disorder with tetrahydroindolone arylpiperazine compounds
US20090264443A1 (en) *	2008-04-18	2009-10-22	David Helton	Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
AU2009318101A1 (en) *	2008-11-21	2010-05-27	Iroko Cardio Llc	Method for reducing thrombocytopenia and thrombocytopenia-associated mortality
AR086411A1 (es) *	2011-05-20	2013-12-11	Nippon Soda Co	Compuesto heterociclico conteniendo nitrogeno y fungicida para el uso en agricultura y jardineria
JP5841361B2 (ja) *	2011-06-29	2016-01-13	壽製薬株式会社	三環性化合物及びそれを含有する医薬組成物
WO2014005274A1 (zh) *	2012-07-03	2014-01-09	海南卫康制药(潜山)有限公司	多取代的8-氮杂环【3.2.1】辛烷化合物
CA3002144C (en)	2015-10-16	2024-01-23	Eisai R&D Management Co., Ltd.	Ep4 antagonists
WO2020008317A1 (en) *	2018-07-03	2020-01-09	Janssen Pharmaceutica Nv	Acylsufonamide compounds useful as ep3 receptor antagonists
CN112552450A (zh) *	2019-09-10	2021-03-26	天津大学	一种单离子交替共聚物锂盐及其制备方法
WO2024206284A2 (en) *	2023-03-27	2024-10-03	Rutgers, The State University Of New Jersey	Therapeutic compounds
CN119100992B (zh) *	2023-06-02	2025-09-16	帕潘纳(北京)科技有限公司	一种特戈拉赞中间体及其衍生物的制备方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5030632B2 (pt) *	1971-11-29	1975-10-02
DK151884C (da)	1979-03-07	1988-06-13	Pfizer	Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
GB8927981D0 (en) *	1989-12-11	1990-02-14	Ici Plc	Carbamoyl derivative
US5545644A (en) *	1990-10-15	1996-08-13	Pfizer Inc.	Indole derivatives
US5239083A (en) *	1991-03-11	1993-08-24	Kyowa Hakko Kogyo Co., Ltd.	Indole derivatives which inhibit steroid 5α reductase
GB9122590D0 (en) *	1991-10-24	1991-12-04	Lilly Industries Ltd	Pharmaceutical compounds
JPH06297860A (ja) *	1993-04-14	1994-10-25	New Oji Paper Co Ltd	感熱記録体
GB9412719D0 (en)	1994-06-24	1994-08-17	Erba Carlo Spa	Substituted azaindolylidene compounds and process for their preparation
AU3578495A (en) *	1994-09-30	1996-04-26	Nippon Chemiphar Co. Ltd.	Quinoline derivative
WO1997005091A1 (en) *	1995-07-26	1997-02-13	Ono Pharmaceutical Co., Ltd.	Naphthyloxyacetic acid derivatives and drugs comprising the same as active ingredients
EP0882718B1 (en) *	1995-12-28	2005-08-31	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole derivatives
EP1170009B1 (en)	1996-01-22	2004-04-07	Fujisawa Pharmaceutical Co., Ltd.	Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists
CA2258728C (en) *	1996-06-19	2011-09-27	Rhone Poulenc Rorer Limited	Substituted azabicylic compounds and their use as inhibitors of the production of tnf and cyclic amp phosphodiesterase
ZA984040B (en)	1997-05-15	1998-11-20	Ono Pharmaceutical Co	Benzenesulfonamide compounds
WO1999000372A1 (fr)	1997-06-27	1999-01-07	Fujisawa Pharmaceutical Co., Ltd.	Sulfamides et leur utilisation medicale
JP3256513B2 (ja) *	1998-02-11	2002-02-12	ファイザー製薬株式会社	ベンゾイミダゾールシクロオキシゲナーゼ−２阻害剤
US6242493B1 (en)	1998-03-13	2001-06-05	Merck Frosst Canada & Co.	Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
AU764872B2 (en) *	1998-10-23	2003-09-04	Merck Frosst Canada & Co.	Combination product comprising an E-type prostaglandin ligand and a cox-2 selective inhibitor and methods of use
US6348032B1 (en) *	1998-11-23	2002-02-19	Cell Pathways, Inc.	Method of inhibiting neoplastic cells with benzimidazole derivatives
WO2002016311A1 (en) *	2000-08-22	2002-02-28	Ono Pharmaceutical Co., Ltd.	Carboxylic acid derivatives, process for producing the same and drugs containing the same as the active ingredient
TWI314457B (pt)	2001-03-19	2009-09-11	Shionogi & Co
MXPA04001253A (es) *	2001-08-09	2004-06-03	Ono Pharmaceutical Co	Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
MX2007004525A (es) *	2004-10-12	2007-09-19	Decode Genetics Inc	Sulfonamidas biciclicas peri-sustituidas para enfermedad de arteria oclusiva.
WO2007137040A2 (en)	2006-05-16	2007-11-29	Decode Genetics Ehf	7-(acryloyl) indole compositions and methods for making and using same

2005
- 2005-06-27 MX MX2007004525A patent/MX2007004525A/es active IP Right Grant
- 2005-06-27 AT AT05769472T patent/ATE499344T1/de not_active IP Right Cessation
- 2005-06-27 CA CA002583667A patent/CA2583667A1/en not_active Abandoned
- 2005-06-27 NZ NZ554491A patent/NZ554491A/en not_active IP Right Cessation
- 2005-06-27 BR BRPI0516003-0A patent/BRPI0516003A/pt not_active IP Right Cessation
- 2005-06-27 WO PCT/US2005/023009 patent/WO2006044000A1/en not_active Ceased
- 2005-06-27 RU RU2007115410/04A patent/RU2403240C2/ru not_active IP Right Cessation
- 2005-06-27 KR KR1020077010837A patent/KR20070091607A/ko not_active Ceased
- 2005-06-27 DE DE602005026553T patent/DE602005026553D1/de not_active Expired - Lifetime
- 2005-06-27 CN CNA2005800426037A patent/CN101142184A/zh active Pending
- 2005-06-27 EP EP05769472A patent/EP1812388B1/en not_active Expired - Lifetime
- 2005-06-27 US US11/169,161 patent/US7598397B2/en not_active Expired - Fee Related
- 2005-06-27 JP JP2007536680A patent/JP2008515971A/ja active Pending
- 2005-06-27 AU AU2005296305A patent/AU2005296305A1/en not_active Abandoned
2007
- 2007-04-11 IL IL182488A patent/IL182488A0/en unknown
- 2007-05-02 NO NO20072288A patent/NO20072288L/no not_active Application Discontinuation
2009
- 2009-08-03 US US12/534,390 patent/US20090291948A1/en not_active Abandoned

Also Published As

Publication number	Publication date
EP1812388A1 (en)	2007-08-01
US20060079520A1 (en)	2006-04-13
US7598397B2 (en)	2009-10-06
JP2008515971A (ja)	2008-05-15
WO2006044000A1 (en)	2006-04-27
EP1812388B1 (en)	2011-02-23
IL182488A0 (en)	2007-09-20
CA2583667A1 (en)	2006-04-27
MX2007004525A (es)	2007-09-19
ATE499344T1 (de)	2011-03-15
CN101142184A (zh)	2008-03-12
NZ554491A (en)	2009-07-31
KR20070091607A (ko)	2007-09-11
DE602005026553D1 (de)	2011-04-07
NO20072288L (no)	2007-06-25
RU2403240C2 (ru)	2010-11-10
RU2007115410A (ru)	2008-11-10
US20090291948A1 (en)	2009-11-26
AU2005296305A1 (en)	2006-04-27

Legal Events

Date	Code	Title	Description
2009-03-31	B25C	Requirement related to requested transfer of rights	Owner name: DECODE GENETICS, INC. (US) Free format text: A FIM DE ATENDER O SOLICITADO NA PETICAO DE TRANSFERENCIA NO 020080091066/RJ DE 30/06/2008, QUEIRAREAPRESENTAR O DOCUMENTO DE CESSAO COM A DEVIDA LEGALIZACAO CONSULAR.
2009-09-29	B25A	Requested transfer of rights approved	Owner name: DECODE GENETICS EHF (IS) Free format text: TRANSFERIDO DE: DECODE GENETICS, INC.
2014-05-06	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 9A ANUIDADE.
2014-09-02	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2261 DE 06/05/2014.

Publication	Publication Date	Title
NO329884B1 (no)	2011-01-17	Indolderivater, farmasoytisk formulering, anvendelse av forbindelsene, fremgangsmate for fremstilling derav samt mellomprodukter for anvendelse i fremgangsmaten
ECSP056194A (es)	2006-04-19	Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de quinasa
UY30711A1 (es)	2008-07-03	Nuevos derivados de 1,4-benzotiepina-1, 1-cioxido, método para su preparacion, productos farmacéuticos que comprenden estos compuestos y su uso.-
AU4818000A (en)	2000-11-21	Substituted 4-oxo-quinoline-3-carboxamides: gaba brain receptor ligands
EA017278B9 (ru)	2013-01-30	Соединения азаиндазола и способы применения
EA201300342A1 (ru)	2014-02-28	Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
NO20073664L (no)	2007-09-28	Peptider med neuropeptid-2-reseptor (Y2R) agonist aktivitet
CY1112376T1 (el)	2015-12-09	Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
CY1114803T1 (el)	2016-12-14	Παραγωγα πυριμιδινο σουλφοναμιδιου ως ρυθμιστες υποδοχεων χημειοκινης
MXPA05013733A (es)	2006-03-08	2-aminobenzotiazoles como agonistas inversos del receptor de cb1.
ECSP055701A (es)	2005-05-30	Nuevos derivados de pirimidinamida y el uso de los mismos
UY27969A1 (es)	2004-04-30	Formulaciones que comprenden un compuesto de indolinona
WO2008067399A3 (en)	2008-09-25	Controlled-release multi-layer formulation of piperazine-piperidine antagonists and agonists of the 5-th1a receptor having enhanced intestinal dissolution
BR0309463A (pt)	2005-02-09	Derivados de 1,2,3,4,7,8-hexaidro-6h-[1,4]diazepino[6,7,1-ij]quinolina como agentes antipsicóticos e antiobesidade
BRPI0517417A (pt)	2008-10-07	composto, uso de um composto ou um éster do mesmo,composição farmacêutica, e, método para a triagem de ligandos do receptor de prostanóide seletivos
BRPI0316895C1 (pt)	2021-05-25	composto, processo para a preparação do composto, composição farmacêutica e uso do composto
ATE409188T1 (de)	2008-10-15	Naphthyridinverbindungen
HUP0401805A2 (hu)	2004-12-28	Pulmonális betegségek kezelésére szolgáló vegyületek
BRPI0615158A8 (pt)	2018-03-06	composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição, e para preparar um composto.
DE602006018713D1 (de)	2011-01-20	Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate
MX2007003545A (es)	2007-05-18	Composiciones y metodos para tratar trastornos cognitivos.
ZA200900165B (en)	2009-12-30	4-amino-3-arylamino-6-arylpyrazolo[3,4-D]pyrimidine derivatives, methods for their preparation and their use as antiviral agents
BRPI0716087A2 (pt)	2013-10-01	composiÇço, uso de um agonista de receptor de glicocorticàide dissociado, uma prà-droga do mesmo, um sal farmaceuticamente aceitÁvel do mesmo ou um Éster farmaceuticamente aceitÁvel do mesmo, e, mÉtodo para produzir uma composiÇço para tratar ou evitar glaucoma ou sua progressço
ATE399156T1 (de)	2008-07-15	Neue indol- oder benzimidazol-derivate
ECSP066318A (es)	2006-07-28	Composición para la liberación de una base debil por un periodo extendido de tiempo